All In Biotech

Drug Trial Radar · NCT07005557

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

Study Evaluating Node-positive, ER+/HER2- In Older (≥65 Years) Breast Cancer Patients for Chemotherapy Exemption: A Randomized, Open-label, Multicenter Phase III Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,244 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,244

Planned (sponsor's estimate)

Start

Jun 15, 2025

Primary completion

May 15, 2030

Study completion May 15, 2035

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged \>65 years) with lymph node-positive, HR+/HER2- breast cancer.

Conditions

  • Breast Cancer
  • Adjuvant Therapy

Interventions

  • ChemotherapyDrug

    Chemotherapy options at physician's discretion: TC, EC-T(wP), or capecitabine.

  • CDK4/6 InhibitorDrug

    All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)

  • Endocrine therapyDrug

    Endocrine therapy (letrozole/anastrozole/exemestane)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-years Invasive disease free survivalTime frame: 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.